Sutro Biopharma Inc STRO.OQ STRO.O is expected to show a fall in quarterly revenue when it reports results for the period ending June 30 2025
The South San Francisco California-based company is expected to report a 51.2% decrease in revenue to $12.544 million from $25.71 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Sutro Biopharma Inc is for a loss of 49 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 17.1% in the last three months.
Wall Street's median 12-month price target for Sutro Biopharma Inc is $3.00, above its last closing price of $0.96.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.70 | -0.71 | -0.91 | Missed | -28.6 |
Dec. 31 2025 | -0.78 | -0.83 | -0.89 | Missed | -7.1 |
Sep. 30 2024 | -0.73 | -0.73 | -0.59 | Beat | 19.7 |
Jun. 30 2024 | -0.76 | -0.79 | -0.59 | Beat | 25.5 |
Mar. 31 2024 | -0.88 | -0.92 | -0.95 | Missed | -3 |
Dec. 31 2023 | -0.82 | 0.52 | Beat | 163.2 | |
Sep. 30 2023 | -0.74 | -0.74 | -0.81 | Missed | -10.1 |
Jun. 30 2023 | -0.75 | -0.73 | -0.64 | Beat | 12.6 |
This summary was machine generated May 9 at 12:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。